Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H10FN3O4.ClH |
Molecular Weight | 279.653 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12OC3=NC(=N)C(F)=C[N@]3[C@]1([H])O[C@H](CO)[C@H]2O
InChI
InChIKey=RMCFDHVUFKPQRX-CFHSPSGHSA-N
InChI=1S/C9H10FN3O4.ClH/c10-3-1-13-8-6(5(15)4(2-14)16-8)17-9(13)12-7(3)11;/h1,4-6,8,11,14-15H,2H2;1H/t4-,5-,6+,8-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1149046Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/348088
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1149046
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/348088
Flurocitabine is an anti-metabolite that was developed by Hoffmann-La Roche for the treatment of cancer. The drug is metabolized to 2 biologically active substances, AFC (1-beta-D-arabinofuranosyl-5-fluorocytosine) and AFU (arabinofuranosyl-5-fluorouracil). Flurocitabine was tested against stomach cancer, pancreatic cancer, small cell lung cancer and AML, however, the development was terminated in the early phases.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1149046
Curator's Comment: # Hoffmann-La Roche Ltd
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Comparative ultrastructure of submaxillary salivary glands from mice treated with cytosine arabinoside, cyclocytidine, and anhydro-ara-5-fluorocytidine. | 1976 Jul |
|
Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group. | 1978 Feb |
|
Phase I and II clinical study of anhydro-ara-5-fluorocytosine (AAFC) and ICRF-159 combination in adenocarcinoma of digestive origin. | 1978 Winter |
|
Anhydro-ara-5-fluorocytidine (AAFC) in gastrointestinal cancer. A phase II study. | 1980 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/93030
Curator's Comment: http://ascopubs.org/doi/pdf/10.1200/jco.1992.10.3.484
The maximum tolerated dose is 650 mg/m2 I.V. weekly (stomach cancer). In acute nonlymphocytic leukemia the dose is 800 mg/m2 (600mg/m2 in children) given every 12 hours until marrow hypocellularity is achieved. In Small-Cell Lung Cancer the dose is 15-20 mg/m2 IV given daily for 5 days every 3 weeks or 33-40 mg/m2 IV given weekly.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
386064MQOR
Created by
admin on Sat Dec 16 08:55:08 GMT 2023 , Edited by admin on Sat Dec 16 08:55:08 GMT 2023
|
PRIMARY | |||
|
166641
Created by
admin on Sat Dec 16 08:55:08 GMT 2023 , Edited by admin on Sat Dec 16 08:55:08 GMT 2023
|
PRIMARY | |||
|
3035515
Created by
admin on Sat Dec 16 08:55:08 GMT 2023 , Edited by admin on Sat Dec 16 08:55:08 GMT 2023
|
PRIMARY | |||
|
40505-45-1
Created by
admin on Sat Dec 16 08:55:08 GMT 2023 , Edited by admin on Sat Dec 16 08:55:08 GMT 2023
|
PRIMARY | |||
|
DTXSID50960908
Created by
admin on Sat Dec 16 08:55:08 GMT 2023 , Edited by admin on Sat Dec 16 08:55:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD